AstraZeneca Pharma India Expectations for 2026

AstraZeneca Pharma I...

BSE:506820

Rp 8.415,50

Rp0,00 (0,00%)

8.415,50 Rp

Rp0,00 (0,00%)

End-of-day quote: 03/27/2026

AstraZeneca Pharma India Stock Value

The analyst rating for BSE:506820 is currently sf_Data Unavailable.

AstraZeneca Pharma India Company Info

EPS Growth 5Y

0,00%

Market Cap

Rp210,39 B

Long-Term Debt

Rp0,63 B

Annual earnings

05/30/2026

Dividend

Rp31,98

Dividend Yield

0,38%

Founded

1979

Industry

Health Care

Country

India

Website

AstraZeneca Pharma India

ISIN Number

INE203A01020

Website

http://www.astrazeneca.in

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

There are currently no price targets available for this stock.

In the last five quarters, AstraZeneca Pharma India’s Price Target has risen from Rp0,00 to Rp8.415,50 - a 100,00% increase.

Top growth stocks in the health care sector (5Y.)

What does AstraZeneca Pharma India do?

AstraZeneca Pharma India Limited (AstraZeneca) operates in the pharmaceutical industry, focusing on the development, manufacturing, and marketing of pharmaceutical products across various therapeutic domains. The company operates primarily within the pharmaceutical sector, with a well-established presence in the production of various dosage forms, including tablets, injectables, and inhalation products. The company is also actively involved in clinical research, offering clinical trial services...

Business Segments

The company operates primarily within a single business segment focused on pharmaceuticals. However, its broad range of products can be categorized into significant therapeutic areas such as oncology, cardiovascular, renal, metabolism, and respiratory diseases. Each category encompasses numerous products that have been meticulously developed to ensure efficacy and safety for patients.

The pharmaceutical division is responsible for the sale of a diverse range of products, including oral medications in the form of tablets and injectables for systemic administration. AstraZeneca’s leading injectable products emphasize the company’s capabilities in manufacturing complex formulations that require advanced technology and precision. The company pursues innovation by developing inhalation therapies designed to treat respiratory ailments, showcasing its versatility in addressing diverse patient needs.

In addition to these product offerings, the company emphasizes the importance of conducting clinical trials. The dedicated team works closely with related parties to recruit participants and carry out research that leads to new product registrations, thereby enhancing the company’s product portfolio. The clinical development services pave the way for gaining insights into real-world applications and patient responses, ensuring that products are effective and tailored to meet treatment goals.

Business Strategy

The company’s business strategy revolves around delivering high-quality pharmaceutical products that effectively meet patient needs while ensuring robust growth in competitive markets. The strategic focus includes investing in research and development to foster innovation, thereby developing new drugs aimed at various health conditions. By prioritizing R&D, the company is committed to identifying unmet medical needs and devising solutions that can significantly improve patient outcomes.

The company is keenly aware of the importance of collaborations for enhancing its capabilities in product development and market reach. The company actively engages with healthcare professionals, researchers, and organizations to forge partnerships that enhance clinical research and expedite the commercialization of new therapies. Such collaborations facilitate knowledge sharing and technology transfer, ultimately leading to superior health solutions.

Products and Services

The company offers a comprehensive range of products and services primarily aimed at addressing various health needs. The company's product lineup includes a variety of pharmaceutical formulations tailored for therapeutic areas such as oncology, cardiovascular, renal, metabolism, and respiratory diseases.

Within its product portfolio, the company manufactures and markets a significant number of oral medications, with tablets being one of the most prevalent forms. These are designed for maximum efficacy and ease of administration, ensuring that patients have access to necessary treatments that can be taken conveniently.

Injectable products represent another vital segment of AstraZeneca’s offerings. These formulations are often used for systemic effects and are crucial in treating more complex health conditions where oral administration may not be viable. The injectables produced by the company are developed using advanced technologies, ensuring they meet the highest standards of safety and efficacy.

Inhalation therapies are also a key component of the company’s portfolio, particularly for the management of respiratory conditions. The development of these products is indicative of AstraZeneca's commitment to addressing chronic illnesses that significantly affect patient quality of life.

In addition to the array of medications, the company also provides clinical trial services. This includes working with related parties to conduct research studies aimed at gaining insights into the safety and efficacy of new treatments. The clinical services offered are vital for ongoing drug development programs and contribute to bringing innovative products to market.

Geographical Markets Served

The company serves a diverse array of geographical markets, focusing primarily on sales to customers within India while also extending its reach to international markets. The emphasis on both local and international sales reflects the company’s strategy to capitalize on growth opportunities across different regions, allowing for a more expansive market presence.

Seasonality

The demand for pharmaceutical products generally remains consistent throughout the year. This stability allows the company to maintain a steady production schedule and ensures that medications are always available for patients who depend on them. The company’s product offerings cover a wide range of therapeutic areas, providing treatments for chronic and acute conditions that require consistent management regardless of the season.

Customers

The company serves a diverse customer base that includes hospitals, healthcare providers, clinics, and pharmacies. The company’s patients encompass individuals with various health conditions requiring treatment across multiple therapeutic areas. The company’s clientele consists of both public and private healthcare institutions.

Sales and Marketing

The company employs a multi-faceted approach to its sales and marketing strategies, leveraging various distribution channels to ensure its products reach the intended end-users effectively. The company utilizes a combination of direct sales, collaborations with distributors, and partnerships with healthcare providers.

The marketing strategies are built around educating healthcare professionals about the therapeutic benefits of the company’s products, fostering long-term relationships within the healthcare community. Promotional activities often include detailing by sales representatives to physicians, hosting workshops, and participating in medical conferences to enhance visibility and engagement.

The distribution channels are structured to ensure prompt delivery of products to pharmacies, hospitals, and healthcare institutions. AstraZeneca employs advanced logistics solutions to facilitate efficient supply chain management, ensuring that products are readily available when needed.

History

AstraZeneca Pharma India Limited was founded in 1979. The company was incorporated in 1979.

AstraZeneca Pharma India Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Sales:** 100% (2026) **TOP 3 Markets:** 1. **India:** 65% 2. **Southeast Asia:** 20% 3. **Middle East and North Africa (MENA):** 10% AstraZeneca Pharma India Limited generates all its sales from the pharmaceutical industry. The Indian market is the most significant for the company...

At which locations are the company’s products manufactured?

**Production Sites:** Bangalore, India AstraZeneca Pharma India Limited mainly produces its products in Bangalore. The production facility there is one of the most important for the company and plays a central role in the manufacturing and delivery of pharmaceutical products for the Indian market....

What strategy does AstraZeneca Pharma India pursue for future growth?

**Strategic Focus Points:** - **Research and Development:** Increase investments in R&D by 20% (2025) - **Market Expansion:** Targeted expansion in emerging markets - **Sustainability:** Introduction of environmentally friendly production processes by 2030 AstraZeneca Pharma India Limited is pu...

Which raw materials are imported and from which countries?

**Main raw materials:** Active pharmaceutical ingredients (APIs), excipients, packaging materials **Countries of origin:** USA, China, Germany, Switzerland AstraZeneca Pharma India Limited mainly imports active pharmaceutical ingredients (APIs) that are essential for the production of their pharm...

How strong is the company’s competitive advantage?

**Market share in India:** 5% (estimated 2026) **R&D expenses:** 12% of revenue (2025) **Product diversification:** Over 30 products in the portfolio (2026) AstraZeneca Pharma India Limited has a significant competitive advantage through its strong research and development, accounting for a...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 30% (estimated for 2026) **Insider Buys/Sells:** No significant transactions in the last year (2025) The institutional investor share in AstraZeneca Pharma India Limited is estimated to be around 30%. This reflects the confidence of institutional investors in the...

What percentage market share does AstraZeneca Pharma India have?

**Market share of AstraZeneca Pharma India Limited:** Estimated 3-5% (2026) **Top competitors and their market shares:** 1. **Sun Pharmaceutical Industries Ltd.:** 8-10% 2. **Cipla Ltd.:** 7-9% 3. **Dr. Reddy's Laboratories Ltd.:** 6-8% 4. **Lupin Ltd.:** 5-7% 5. **Aurobindo Pharma Ltd.:** 4-...

Is AstraZeneca Pharma India stock currently a good investment?

**Revenue Growth:** 10.5% (2025) **Profit Growth:** 8.2% (2025) **Research and Development Expenses:** 15% of Revenue (2025) AstraZeneca Pharma India Limited achieved solid revenue growth of 10.5% in 2025, attributed to successful introduction of new drugs and increased demand in various therapy ar...

Does AstraZeneca Pharma India pay a dividend – and how reliable is the payout?

**Dividend Yield:** 1.5% (estimated for 2026) **Dividend History:** Regular payouts in recent years AstraZeneca Pharma India Limited has pursued a consistent dividend policy in recent years. The dividend yield is currently estimated at 1.5%, which can be considered moderate compared to other comp...

New support ticket

Explore

AstraZeneca Pharma India Stock Value

AstraZeneca Pharma India Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does AstraZeneca Pharma India do?

AstraZeneca Pharma India Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

AstraZeneca Pharma India Stock Value

AstraZeneca Pharma India Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does AstraZeneca Pharma India do?

AstraZeneca Pharma India Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.